Insulet Corporation (PODD) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-18

Business type: Treadmill

How it makes money

Patients pay for disposable Pods that are replaced frequently.

People with insulin-dependent diabetes pay for the Omnipod platform to manage blood glucose levels. Frequent replacement of disposable Pods drives recurring revenue.

What protects it: the moat

Management claims its patented design and clinical evidence protect its market position.

Management claims the unique patented design of the Omnipod provides a competitive advantage. The company also uses clinical studies to secure reimbursement from insurance providers.

What growth costs

It must invest in new manufacturing plants and research to support growth.

The company is expanding its production capacity by building new plants in Malaysia and Costa Rica. It also invests in clinical trials and product development.

What could damage it

Losing coverage from third-party payors could permanently impair revenue.

If insurance companies or government agencies stop covering the cost of the products, the company's ability to sell to patients would be severely diminished.

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

More on PODD

Other companies in Medical Devices